Association of Tumor-Infiltrating Lymphocytes (TILs) and Immune Gene Expression Signatures (iGES) With Pathologic Complete Response (pCR) in the Presence of Clinical Parameters Using the Combined CALGB 40601 and PAMELA CohortĮTable 6. Association of Tumor-Infiltrating Lymphocytes (TILs) and Immune Gene Expression Signatures (iGES) With Pathologic Complete Response (pCR) in the Combined CALGB 40601 and PAMELA Data SetĮTable 5. Correlation of Tumor-Infiltrating Lymphocytes (TILs) and Immune Gene Expression Signatures (iGES) in CALGB 40601 and PAMELAĮTable 4. Comparison of Baseline Characteristics of the Patients From the CALGB 40601 Event-Free Survival (EFS) and Landmark SubpopulationsĮTable 3. List of Immune Gene Expression Signatures, Signature Class, PMID, and Genes Within a SignatureĮTable 2. Accuracy Metrics of the Univariable Immune Biomarker Models for Pathologic Complete Response (pCR) PredictionĮTable 1. Rates of Pathologic Complete Response (pCR) According to Immune Gene Expression Signature (iGES) LevelsĮFigure 7.
Association Between the Spearman Correlation Coefficients of Tumor-Infiltrating Lymphocytes (TILs) and Immune Gene Expression Signatures (iGES) in CALGB 40601 and PAMELAĮFigure 6. Correlation Between Tumor-Infiltrating Lymphocytes (TILs) Levels and Immune Gene Expression Signatures (iGES)ĮFigure 5. Comparison of Stromal Tumor-Infiltrating Lymphocytes (TILs) Levels by Hormone Receptor Status and Intrinsic Subtype in CALGB 40601 and PAMELAĮFigure 4. Distribution of Tumor-Infiltrating Lymphocytes Infiltration by Clinical TrialĮFigure 3.
0 kommentar(er)
